1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers is sponsored by European Commission — Horizon Europe. Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: Patients with refractory cancers and their caregivers/families will have access to optimised, tailored and affordable immunotherapeutic interventions that increase their quality of life, across European regions, EU Member States and Associated Countries; Healthcare professionals and academia will have access to clinical evidence, on effectiveness of immunotherapeutic interventions, to deploy evidence-based treatment interventions with improved patient selection that improve outcomes in real life, i.e. in routine healthcare, for patients with refractory cancers who often present with co-morbidities; National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries will have the evidence to implement and reimburse optimised and affordable immunotherapeutic interventions in their healthcare systems, including in everyday medical practice. Scope: While cancer research and innovation have generated novel treatment options, patients with refractory cancers across Europe need access to more effective, affordable and tailored cancer immunotherapeutic interventions which keep up with increasing demands in a complex and fragmented oncology healthcare landscape with spiralling healthcare costs. Pragmatic clinical trials focus on choosing between care options. Pragmatic trials evaluate effectiveness of interventions in settings that more closely resemble routine, real-world settings, aiming to produce evidence directly applicable to clinical practice [1] . Proposals should address all the following: Conduct randomised or cluster-randomised academic investigator-initiated [2] pragmatic clinical trials that benefit patients with refractory cancers - at any stage of the disease, for any cancer subtype, in any age group or part of society - to deliver effective, affordable and tailored immunotherapeutic interventions for implementation by healthcare systems at the level of local communities, European regions, EU Member States and Associated Countries. All data should be disaggregated by sex, gender, age and other relevant variables, such as by measures of socio-economic status or ethnicity. Translational research is limited to supporting biomarker-informed patient stratification and the conduct and analyses of the proposed clinical trial(s). The primary and secondary endpoints of the pragmatic clinical trials should target overall survival, patient-reported outcomes and quality of life issues considered important by and for cancer patients and their caregivers/families. Such endpoints should be defined together with patients and their caregivers/families through research that stimulates social innovation and supports end-user engagement using participative research models. The chosen treatment intervention(s) should be adapted to the particular needs of the target population and to the specificities of the provision of care at local, regional, or national level, duly reflecting the diversity across EU Member States and Associated Countries. Furthermore, affordability and accessibility should be taken into account. Applicants should include an appropriate mix of stakeholders from various disciplines, sectors [3] and regional as well as national health authorities, and provide details of the clinical study(ies) in the dedicated annex using the template provided in the submission system. The successful proposals are expected to build on resources made available by the Knowledge Centre on Cancer (KCC) [4] to foster EU alignment and coordination. Successful proposals will be asked to join the 'Diagnosis and Treatment' cluster for the EU Cancer Mission [5] and should include a budget for networking, attendance at meetings, and joint activities [6] . The Commission will facilitate coordination of these activities. [1] Some e
Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Health
Keywords: Anticancer therapy, Diagnostic tools (e.g. genetic, imaging), Haematology, Medical devices, Paediatrics, Pharmacogenomics, Pharmacology, pharmacogenomics, drug discovery and design, drug therapy, Radiation therapy, Stem cell therapy, Surgery, Clinical Trials, Rare Cancers
Get alerted about grants like this
Get emailed when new opportunities from “European Commission — Horizon Europe” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Open to legal entities established in EU Member States and countries associated to Horizon Europe (including EEA/EFTA countries, and other associated third countries). Action type: HORIZON-RIA HORIZON Research and Innovation Actions. Additional conditions: "> General conditions 1. Admissibility Conditions: Proposal page limit and layout described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes. Proposal page limits and layout: described in Part B of the Application Form available in the Submission System. 2. Eligible Countries described in Annex B of the Work Programme General Annexes. A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making... See the official call documentation on the F&T Portal for full eligibility criteria and participation rules. Confirm the full requirements in the official notice before applying.
The current listing shows €124.2M total budget (~$134.1M USD) ; up to €5M per project ; ~3 grants expected. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers are due September 15, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers is funded by European Commission — Horizon Europe. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The European Capital of Innovation Award Rising Innovator Category HORIZON-EIC-2026-PRIZE-ICAPITAL is sponsored by European Commission — Horizon Europe. Expected Impact: The European Capital of Innovation Awards aim to champion inspiring cases of municipality-enabled innovation flourishing in cities. The Awards are a prestigious recognition for city administrators who are courageous enough to open up their governance practices to experimentation, to boost innovation by all means, to be a role model for other cities, and to push the boundaries of technology for the benefit of their citizens. In addition to the monetary reward, the prize brings high visibility in the form of renewed public interest and increased media coverage. A European prize to the most innovative cities ecosystems. The award will raise the profile of the cities that have developed and implemented innovative policies; established frameworks that boost breakthrough innovation; enhanced the city attractiveness towards investors, industry, enterprises and talents; helped to open up connections and strengthen links with other cities, promoting the replication of best practices in the innovation field; enhanced citizens’ involvement in the decision-making process; and supported cities resilience. Expected Outcome: The European Capital of Innovation Awards aim to champion inspiring cases of municipality-enabled innovation flourishing in cities. The Awards are a prestigious recognition for city administrators who are courageous enough to open up their governance practices to experimentation, to boost innovation by all means, to be a role model for other cities, and to push the boundaries of technology for the benefit of their citizens. In addition to the monetary reward, the prize brings high visibility in the form of renewed public interest and increased media coverage. A European prize to the most innovative cities ecosystems. The award will raise the profile of the cities that have developed and implemented innovative policies; established frameworks that boost breakthrough innovation; enhanced the city attractiveness towards investors, industry, enterprises and talents; helped to open up connections and strengthen links with other cities, promoting the replication of best practices in the innovation field; enhanced citizens’ involvement in the decision-making process; and supported cities resilience. Objective: The traditional city innovation ecosystem is opening to new models of innovation engaging citizens, ensuring their involvement in the decision-making process, and reinforcing democracy and rights. An increasing number of cities are acting as test beds for innovation and run people-driven initiatives to find solutions to societal challenges, such as climate change, digitalisation, sustainable growth or social cohesion, including through new endeavours such as nature-based solutions and EU Missions The public domain is particularly challenged with finding effective ways to ensure the mainstreaming of these practices into the ordinary urban development process. Successful practices are particularly crucial to enhance the city’s capacity to attract and retain new resources, funds and talents to stimulate the growth of breakthrough innovations. Moreover, collaboration and strengthening synergies among innovation ecosystems boost cities’ development and resilience to tackle urban challenges and inspires many other cities follow a similar path. The New European Innovation Agenda207 sets out a vision for harnessing the power of innovation to drive economic growth, social progress, and contribute to the green and digital transition in Europe. The agenda emphasizes the need for strategic investments in key technologies, including deep tech, and for strengthening and better connecting innovation ecosystems through stronger collaboration between regions, to close the innovation divide. For this reason, the European Capital of Innovation Awards will recognize the cities’ role as catalysers of the local innovation ecosystem and will stimulate new activities aimed at boosting game-changing innovation. Programme areas: Horizon Europe (HORIZON), Innovative Europe, The European Innovation Council (EIC)
ERC ADVANCED GRANTS is sponsored by European Commission — Horizon Europe. Expected Outcome: Objectives and profile of the ERC Advanced Grant Principal Investigator The objective of the Advanced Grant is to support excellent Principal Investigators that are established research leaders. An ERC Advanced Grant Principal Investigator is expected to be an active researcher with a track record of significant research achievements. Size of ERC Advanced Grants Advanced Grants may be awarded up to a maximum of EUR 2 500 000 for a period of 5 years . The maximum amount of the grants is reduced pro rata temporis for projects of a shorter duration. Additional funding up to EUR 1 000 000 * can be requested to cover further eligible costs (e.g. start-up costs, major equipment, access to large facilities, major experimental and field work costs) when these are necessary to carry out the proposed work. The requests for additional funding must be duly justified in the proposal. Additional funding is not subject to pro rata temporis reduction for projects of shorter duration. * Except for Principal Investigators in Starting, Consolidator, or Advanced Grant re-locating to the EU or an Associated Country from elsewhere to take up their ERC grant. In this case, the maximum additional funding shall be EUR 2 000 000. The Advanced Grant is awarded as a single lump sum contribution for the entirety of the project (broken down by beneficiaries – where applicable) based on a realistic estimate of the actual cost of the project, and fully covering the work to be implemented in the proposed action. For further information, please see the ERC Work Programme 2026 . Programme areas: Horizon Europe (HORIZON), Excellent Science, European Research Council (ERC) Keywords: Advanced Grant, ERC, European Research Council, Excellent Science, Frontier Research
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
This initiative will stimulate and support innovative research by small business concerns that may lead to the development of novel technologies for the early diagnosis, monitoring and treatment of micro and macro vascular complications of diabetes which are associated with significant morbidity and mortality of the disease and high costs to the health care system. Funding Opportunity Number: PA-14-058. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL.
The EU's last major Horizon Europe work programme puts €14B on the table through 2027. A strategic breakdown of budgets, deadlines, eligibility, and how US-based teams can compete.
Read articleEUR 307M in Horizon Europe AI calls closed April 15, 2026. US researchers can participate — but the rules are specific. Here is how to navigate them.
Read articleThe EU committed €900 million to lure researchers with relocation grants worth up to €2 million each. France placed 41 of 46 recruits from the US. Here is what the global talent war means for American research institutions and grant seekers.
Read article